Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis: Short communication

Transplant Infectious Disease

Volumn 11, Issue 1, 2009, Pages 89-93

  Kontoyiannis, D P ^a,b   Ratanatharathorn, V ^c   Young, J A ^d   Raymond, J ^e   Laverdiere M ^f   Denning, D W ^g   Patterson, T F ^h   Facklam, D ⁱ   Kovanda, L ⁱ   Arnold, L ⁱ   Lau, W ⁱ   Buell, D ⁱ   Marr, K A ^j  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e WESTERN PENNSYLVANIA HOSPITAL   (United States)

^f MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

Aspergillus; Combination therapy; Invasive aspergillosis; Micafungin; Stem cell transplantation

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ADULT; ARTHRALGIA; ARTICLE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG TOLERABILITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CHILD; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; LIPOPEPTIDES; TREATMENT OUTCOME;

EID: 58649107659     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2008.00349.x     Document Type: Article

References (15)

1. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006 162 : 1 15.
2. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007 44 : 531 540.
3. Denning DW. Echinocandin antifungal drugs. Lancet 2003 362 : 1142 1151.
4. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006 107 : 2888 2897.
5. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006 53 : 337 349.
6. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 34 : 7 14.
7. Lewis RE, Kontoyiannis DP. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Update 2003 6 : 257 269.
8. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006 81 : 320 326.
9. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004 39 : 797 802.
10. Caillot D, Thiébaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007 110 : 2740 2746.
11. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination of caspofungin and liposomal amphotericin B. Cancer 2003 97 : 1025 1032.
12. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003 98 : 292 296.
13. Kontoyiannis DP, Boktour M, Hanna H, et al. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 2005 103 : 2334 2337.
14. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005 40 : S392 S400.
15. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 415.